Upregulation of type I collagen by TGF-β in mesangial cells is blocked by PPARγ activation

We found that peroxisome proliferator-activated receptor-γ (PPARγ) mRNA was reduced by 77% in glomeruli of diabetic mice. Because mesangial cells play an important role in diabetic nephropathy, we ...

[1]  C. Marcantoni,et al.  Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. , 2001, Kidney international.

[2]  W. Hsueh,et al.  Expression and Function of Peroxisome Proliferator–Activated Receptor-γ in Mesangial Cells , 2001 .

[3]  G. Striker,et al.  Expression and regulation of estrogen receptors in mesangial cells: influence on matrix metalloproteinase-9. , 2001, Journal of the American Society of Nephrology : JASN.

[4]  S. Hong,et al.  Extracellular signal-regulated kinase mediates stimulation of TGF-beta1 and matrix by high glucose in mesangial cells. , 2000, Journal of the American Society of Nephrology : JASN.

[5]  R. Routh,et al.  Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion. , 2000, Kidney international.

[6]  T. Willson,et al.  Peroxisome Proliferator-activated Receptors and Hepatic Stellate Cell Activation* , 2000, The Journal of Biological Chemistry.

[7]  G. Striker,et al.  MATRIX ACCUMULATION IN MESANGIAL CELLS EXPOSED TO CYCLOSPORINE A REQUIRES A PERMISSIVE GENETIC BACKGROUND , 2000, Transplantation.

[8]  S. Silbiger,et al.  Selective estrogen receptor modulators suppress mesangial cell collagen synthesis. , 2000, American journal of physiology. Renal physiology.

[9]  M. Fujishima,et al.  Peroxisome proliferator-activated receptor gamma1 (PPARgamma1) expresses in rat mesangial cells and PPARgamma agonists modulate its differentiation. , 2000, Biochimica et biophysica acta.

[10]  K. Isshiki,et al.  Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. , 2000, Diabetes.

[11]  Sander Kersten,et al.  Roles of PPARs in health and disease , 2000, Nature.

[12]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: insight into multiple cellular functions. , 2000, Mutation research.

[13]  M. Lazar,et al.  A Dominant-negative Peroxisome Proliferator-activated Receptor γ (PPARγ) Mutant Is a Constitutive Repressor and Inhibits PPARγ-mediated Adipogenesis* , 2000, The Journal of Biological Chemistry.

[14]  Taosheng Chen,et al.  Activation of Human T Lymphocytes Is Inhibited by Peroxisome Proliferator-activated Receptor γ (PPARγ) Agonists , 2000, The Journal of Biological Chemistry.

[15]  S. O’Rahilly,et al.  Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension , 1999, Nature.

[16]  B. Staels,et al.  Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. , 1999, Circulation research.

[17]  G. Striker,et al.  IGF-1 decreases collagen degradation in diabetic NOD mesangial cells: implications for diabetic nephropathy. , 1999, Diabetes.

[18]  G. Striker,et al.  Glomerular endothelial cells synthesize collagens but little gelatinase A and B. , 1998, Journal of the American Society of Nephrology : JASN.

[19]  K. Sharma,et al.  Transcriptional activation of transforming growth factor-beta1 in mesangial cell culture by high glucose concentration. , 1998, Kidney international.

[20]  H. Schnaper,et al.  Regulation of human mesangial cell collagen expression by transforming growth factor-β1. , 1998, American journal of physiology. Renal physiology.

[21]  J. Clapham,et al.  Peroxisome Proliferator-Activated Receptor-γ Agonist, Rosiglitazone, Protects Against Nephropathy and Pancreatic Islet Abnormalities in Zucker Fatty Rats , 1998, Diabetes.

[22]  G. Struhl,et al.  Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb , 1998, Nature.

[23]  B. Seed,et al.  PPAR-γ agonists inhibit production of monocyte inflammatory cytokines , 1998, Nature.

[24]  M. Breyer,et al.  Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. , 1997, American journal of physiology. Renal physiology.

[25]  S. McGowan,et al.  Peroxisome proliferators alter lipid acquisition and elastin gene expression in neonatal rat lung fibroblasts. , 1997, The American journal of physiology.

[26]  T. Miyazaki,et al.  Troglitazone has a scavenging effect on reactive oxygen species. , 1997, Biochemical and biophysical research communications.

[27]  M. Jimenez-Linan,et al.  Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. , 1997, The Journal of clinical investigation.

[28]  K. Sharma,et al.  Increased Renal Production of Transforming Growth Factor-β1 in Patients with Type II Diabetes , 1997, Diabetes.

[29]  G. Striker,et al.  Mesangial cells from transgenic mice with progressive glomerulosclerosis exhibit stable, phenotypic changes including undetectable MMP-9 and increased type IV collagen. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[30]  Y. Akai,et al.  Quantification of glomerular TGF-β1 mRNA in patients with diabetes mellitus , 1996 .

[31]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[32]  C. Brinckerhoff,et al.  Suppression of collagenase gene expression by all‐trans and 9‐cis retinoic acid is ligand dependent and requires both RARs and RXRs , 1995, Journal of cellular biochemistry.

[33]  G. Striker,et al.  The kidney disease of diabetes mellitus (KDDM): a cell and molecular biology approach. , 1993, Diabetes/metabolism reviews.

[34]  Jeffrey L. Wrana,et al.  TGFβ signals through a heteromeric protein kinase receptor complex , 1992, Cell.

[35]  H. Jacobson,et al.  Mesangial deposition of type I collagen in human glomerulosclerosis. , 1992, Human pathology.

[36]  G. Striker,et al.  Age-related changes in alpha 1- and alpha 2-chain type IV collagen mRNAs in adult mouse glomeruli: competitive PCR. , 1992, The American journal of physiology.

[37]  C. Alpers,et al.  The activated mesangial cell: a glomerular "myofibroblast"? , 1992, Journal of the American Society of Nephrology : JASN.

[38]  G. Striker,et al.  Role of mesangial cells in glomerulosclerosis. , 1991, The Journal of diabetic complications.

[39]  G. Renier,et al.  Differential regulation of macrophage peroxisome proliferator-activated receptor expression by glucose : role of peroxisome proliferator-activated receptors in lipoprotein lipase gene expression. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[40]  G. Striker,et al.  Strain differences rather than hyperglycemia determine the severity of glomerulosclerosis in mice. , 1998, Kidney international.

[41]  S. McGowan,et al.  Peroxisome proliferators alter lipid acquisition and elastin gene expression in neonatal rat lung fibroblasts. , 1997, American journal of physiology. Lung cellular and molecular physiology.

[42]  B. Blumberg,et al.  Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. , 1995, Gene expression.

[43]  G. Striker,et al.  Age-related changes in α1- and α2-chain type IV collagen mRNAs in adult mouse glomeruli : competitive PCR , 1992 .